Viatris Gains Ground as Options Tilt Bullish Ahead of November Print

VTRS has added 5.8% this week and 12% over the past month, arriving at $18.66 with retail attention spiking and options flow turning more call-heavy than at almost any point in the past year.

The most distinctive signal this week comes from the options market. The put/call ratio has drifted up to 0.28, which sounds elevated in absolute terms, but it is only 1.5 standard deviations above its 20-day mean of 0.27. More telling is the absolute level: 0.28 sits near the bottom of the 52-week range, which runs from 0.13 to 0.74. That means options traders are running one of the most call-heavy setups of the past year, not hedging against a slide but adding to upside exposure as the stock climbs. The borrow market tells the same story. Short interest is 3.6% of the free float, up about 3.3% on the week, a modest build but not a meaningful signal on its own. Cost to borrow is a negligible 0.50%, and availability is effectively unconstrained at 3,752% of short interest, with more than 1.1 billion shares available to lend. There is no squeeze pressure here and no urgency in the lending market. Bears are not being squeezed out and are not piling in either. The short score has held flat around 38 all week, confirming the absence of any directional conviction from short sellers.

The Street has done more work on VTRS in recent weeks than the stock's modest profile might suggest. UBS raised its target to $26 on October 5, maintaining Buy, the most aggressive target on the board and now more than 40% above the current price. That followed Oppenheimer's fresh Outperform initiation in late September with a $25 target. The mean target across analysts is $19.70, implying around 5.6% upside from current levels, though the UBS and Oppenheimer targets are pulling that figure upward. Piper Sandler, the most cautious voice in recent moves, lifted its Neutral target to $13 in mid-September, well below where the stock already trades. The factor picture is supportive in places: forward earnings revisions rank in the 92nd percentile, analyst recommendation direction ranks in the 91st, and the dividend score sits at 83. EPS surprise, however, ranks in just the 7th percentile, a notable outlier against that otherwise constructive backdrop.

The alt data adds a less comfortable note for the operating story. CMS Medicaid reimbursement data shows Viatris units reimbursed have fallen for four consecutive quarters and are down 34% year-on-year in Q1 2026 at 121.5 million units. Neither the Medicaid dataset nor any other ORTEX-tracked series for this company has been measured to lead the company's reported figures, so this cannot be called a forward indicator. It is, however, a concrete fact about volume pressure in one of the company's core channels, one that the bear case cited by analysts maps onto directly.

The ownership picture has been active on both sides of the ledger. FMR lifted its stake to 11.0% in a 13G/A filed in September, up from 8.3%, making it the largest disclosed holder at 119 million shares. T. Rowe Price added roughly 4 million shares in Q3 to reach 5.9% of the company. Davis Selected, by contrast, trimmed from 6.8% to 6.5% in its August amendment. All 13D/G positions are as last disclosed around the 5% threshold, and holders dropping below that level may not file again. No activist 13D is on the register.

The next earnings date is November 5. The most recent comparable print, in August, produced a 6.9% one-day drop and a 9.1% loss over the following week. With the stock now 12% higher than a month ago and options traders skewed unusually toward calls, the November release becomes the obvious next test of whether the re-rating since mid-year can survive contact with the actual numbers.